T

Tennessee Retina | Research Department

Research site

(Unclaimed)

Location

345 23rd Avenue North, Suite 350, Nashville, Tennessee, United States of America

Site insights

Top conditions

Top treatments

Razuprotafib

IONIS-FB-LRx

Strontium90 Beta

Fluocinolone Acetonide

Adalimumab

ranibizumab

AVD-104

BI 771716

Pegcetacoplan

AKB-9778

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 15 total trials

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment

Enrolling

Neovascular (Wet) Age-Related Macular Degeneration

Biological: Aflibercept IVT

Biological: 4D-150 IVT

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (SIGLEC)

Investigate the Safety, Pharmacokinetics, and Treatment effects of Single and Multi-dose of Intravitreal AVD-104 in participants with geographic atro...

Enrolling

Macular Degeneration

Geographic Atrophy of the Macula

Drug: AVD-104

Drug: Avacincaptad

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

A study to evaluate the safety and efficacy of YUTIQ® 0.18 mg intravitreal implant for the management of chronic non-infectious posterior segment uve...

Enrolling

Uveitis, Posterior

Drug: Fluocinolone Acetonide Intravitreal Implant 0.18 mg